|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. 5:10.1002/ijc.33588.
2021.
|
|
2
|
Åkesson Å, Adok C and Dahm-Kähler P:
Recurrence and survival in endometrioid endometrial cancer-a
population-based cohort study. Gynecol Oncol. 168:127–134. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
NCCN Clinical practice guidelines in
oncology (NCCN Guidelines), . Uterine Neoplasms: Version1.2024.
Available at:. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdfFebruary
15–2024
|
|
4
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Travaglino A, Raffone A, Raimondo D,
Reppuccia S, Ruggiero A, Arena A, Casadio P, Zullo F, Insabato L,
Seracchioli R and Mollo A: Prognostic significance of CTNNB1
mutation in early stage endometrial carcinoma: A systematic review
and meta-analysis. Arch Gynecol Obstet. 306:423–431. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parrish ML, Broaddus RR and Gladden AB:
Mechanisms of mutant β-catenin in endometrial cancer progression.
Front Oncol. 12:10093452022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Travaglino A, Raffone A, Saccone G, De
Luca C, Mollo A, Mascolo M, De Placido G, Insabato L and Zullo F:
Immunohistochemical nuclear expression of β-catenin as a surrogate
of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol.
151:529–538. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berek JS, Matias-Guiu X, Creutzberg C,
Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D and Concin
N; Endometrial Cancer Staging Subcommittee and FIGO Women's Cancer
Committee, : FIGO staging of endometrial cancer: 2023. Int J
Gynaecol Obstet. 162:383–394. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim G, Kurnit KC, Djordjevic B, Singh C,
Munsell MF, Wang WL, Lazar AJ, Zhang W and Broaddus R: Nuclear
β-catenin localization and mutation of the CTNNB1 gene: A
context-dependent association. Mod Pathol. 31:1553–1559. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
11
|
Stelloo E, Nout RA, Osse EM,
Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik
EM, Nijman HW, Putter H, Bosse T, et al: Improved risk assessment
by integrating molecular and clinicopathological factors in
early-stage endometrial cancer-combined analysis of the PORTEC
cohorts. Clin Cancer Res. 22:4215–4224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurnit KC, Kim GN, Fellman BM, Urbauer DL,
Mills GB, Zhang W and Broaddus RR: CTNNB1 (beta-catenin) mutation
identifies low grade, early stage endometrial cancer patients at
increased risk of recurrence. Mod Pathol. 30:1032–1041. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moroney MR, Davies KD, Wilberger AC,
Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli
SR, Behbakht K and Corr BR: Molecular markers in recurrent stage I,
grade 1 endometrioid endometrial cancers. Gynecol Oncol.
153:517–520. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Costigan DC, Dong F, Nucci MR and Howitt
BE: Clinicopathologic and immunohistochemical correlates of CTNNB1
mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol.
39:119–127. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruz-Caracuel I, López-Janeiro Á,
Heredia-Soto V, Ramón-Patino JL, Yébenes L, Berjón A, Hernández A,
Gallego A, Ruiz P, Redondo A, et al: Clinicopathological features
and prognostic significance of CTNNB1 mutation in low-grade,
early-stage endometrial endometrioid carcinoma. Virchows Arch.
479:1167–1176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tribulo P, Moss JI, Ozawa M, Jiang Z, Tian
XC and Hansen PJ: WNT regulation of embryonic development likely
involves pathways independent of nuclear CTNNB1. Reproduction.
153:405–419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imboden S, Tapia C, Scheiwiller N, Kocbek
V, Altermatt HJ, Janzen J, Mueller MD and McKinnon B: Early-stage
endometrial cancer, CTNNB1 mutations, and the relation between
lymphovascular space invasion and recurrence. Acta Obstet Gynecol
Scand. 99:196–203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kovacs G, Billfeldt NK, Farkas N, Dergez
T, Javorhazy A, Banyai D, Pusztai C and Szanto A: Cytoplasmic
expression of β-catenin is an independent predictor of progression
of conventional renal cell carcinoma: A simple immunostaining
score. Histopathology. 70:273–280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kitson S, Sivalingam VN, Bolton J, McVey
R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse
T, et al: Ki-67 in endometrial cancer: Scoring optimization and
prognostic relevance for window studies. Mod Pathol. 30:459–468.
2017. View Article : Google Scholar : PubMed/NCBI
|
